HeartSciences (NASDAQ:HSCS) Announces Earnings Results

HeartSciences (NASDAQ:HSCS) released its earnings results on Thursday. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.22), Zacks reports.

HeartSciences Stock Performance

NASDAQ HSCS traded down $0.05 during trading hours on Friday, hitting $2.39. The company had a trading volume of 8,205 shares, compared to its average volume of 86,167. The company has a quick ratio of 1.04, a current ratio of 1.19 and a debt-to-equity ratio of 0.16. The firm has a market cap of $7.60 million, a P/E ratio of -0.61 and a beta of 1.78. HeartSciences has a fifty-two week low of $1.63 and a fifty-two week high of $4.30. The business has a fifty day simple moving average of $2.27 and a 200-day simple moving average of $2.50.

Hedge Funds Weigh In On HeartSciences

An institutional investor recently raised its position in HeartSciences stock. DRW Securities LLC increased its position in HeartSciences Inc. (NASDAQ:HSCS) by 13.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 95,065 shares of the company’s stock after acquiring an additional 11,455 shares during the period. DRW Securities LLC owned approximately 2.99% of HeartSciences worth $294,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 17.24% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of HeartSciences in a research note on Wednesday, June 24th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $8.00.

About HeartSciences

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.